TY - JOUR T1 - Mortality in combined pulmonary fibrosis and emphysema patients is determined by the sum of pulmonary fibrosis and emphysema JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00316-2021 VL - 7 IS - 3 SP - 00316-2021 AU - An Zhao AU - Eyjolfur Gudmundsson AU - Nesrin Mogulkoc AU - Mark G. Jones AU - Coline van Moorsel AU - Tamera J. Corte AU - Chiara Romei AU - Recep Savas AU - Christopher J. Brereton AU - Hendrik W. van Es AU - Helen Jo AU - Annalisa De Liperi AU - Omer Unat AU - Katarina Pontoppidan AU - Frouke van Beek AU - Marcel Veltkamp AU - Peter Hopkins AU - Yuben Moodley AU - Alessandro Taliani AU - Laura Tavanti AU - Bahareh Gholipour AU - Arjun Nair AU - Sam Janes AU - Iain Stewart AU - David Barber AU - Daniel C. Alexander AU - Athol U. Wells AU - Joseph Jacob Y1 - 2021/07/01 UR - http://openres.ersjournals.com/content/7/3/00316-2021.abstract N2 - Emphysema is one of the most common pulmonary comorbidities of idiopathic pulmonary fibrosis (IPF), presenting in about one-third of IPF patients [1]. The term combined pulmonary fibrosis and emphysema (CPFE) has been used to describe a potential phenotype characterised by the coexistence of upper lobe-predominant emphysema, lower lobe-predominant fibrosis and relative preservation of lung volumes (forced vital capacity; FVC) in the context of a disproportionately reduced gas transfer (diffusing capacity of the lung for carbon monoxide; DLCO) [1–3]. With regard to patient survival, it remains unclear whether mortality in patients with CPFE reflects the cumulative effects of two disease processes (emphysema and fibrosis), or whether CPFE represents a distinct disease phenotype where outcome is worse than the sum of disease parts (emphysema and fibrosis).In patients with combined pulmonary fibrosis and emphysema, emphysema and fibrosis do not have a synergistic effect that results in worsened survival when compared to IPF patients without emphysema https://bit.ly/35EJMo6 ER -